Cochlear under review after weak first-half result

Cochlear has announced a disappointing first-half result and downgraded its full-year guidance, with the result that the share price has dropped around 10%. We're currently running through the numbers and will listen in to this afternoon's conference call before publishing an update later today or tomorrow. In the meantime, with the stock down 9% since Cochlear loses patent infringement case on 24 Jan 14 (Hold – $57.96), we're placing our recommendation UNDER REVIEW. Note: Our model Growth Portfolio owns shares in Cochlear.

Cochlear has announced a disappointing first-half result and downgraded its full-year guidance, with the result that the share price has dropped around 10%. We're currently running through the numbers and will listen in to this afternoon's conference call before publishing an update later today or tomorrow. In the meantime, with the stock down 9% since Cochlear loses patent infringement case on 24 Jan 14 (Hold – $57.96), we're placing our recommendation UNDER REVIEW.

Note: Our model Growth Portfolio owns shares in Cochlear.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles